Study aim: Determining the effect of oral administration of Royal Jelly on the gene expression of S100A10, S100A9, S100A4, MANGO, OCTB4, BAX, NLRP1, NLRP3, ASC, CCL2, CCL3 and CCL8 molecules Design: Clinical trial containing the patients who infected with Hepatitis B virus of both sexes in the age range of 20 to 60 years in the period from August to December 2021, double-blind, randomized and phase 1 on 50 patients. The oral administration period of Royal Jelly is one month . Settings and conduct: Patients with Hepatitis B referred to Kerman Medical Sciences Hospital will be under the supervision of a specialist and will complete the consent form before entering the study. Before receiving Royal Jelly, 5 ml of blood sample will be taken. Each patient will then receive one gram of Royal Jelly orally daily for one month. After one month, blood samples are taken from each patient again. On all blood samples before and after oral administration of Royal Jelly, the expression of the gene expression of S100A10, S100A9, S100A4, MANGO, OCTB4, BAX, NLRP1, NLRP3, ASC, CCL2, CCL3 and CCL8 molecules will be evaluated using the SYBR Green based real-time PCR assay before receiving Royal Jelly. The researcher will measure the above cases in relation to the blind study. Participants/Inclusion and exclusion criteria: Infected with Hepatitis B Intervention groups: 50 Hepatitis B virus infected patients will be treated with oral administration of royal jelly at a rate of one gram per day for a month. Royal jelly will be used as an intervention agent. Before and after oral administration of Royal Jelly, the gene expression of some immune molecules will be examined using the SYBR Green based real-time PCR assay . The results will be compared before and after oral administration of Royal Jelly in infected patients. Main outcome variables: Gene expression